GlassScriptPhysician profile
Melissa Van Fossen
NPI 1235837865
$2,017.36
in general payments reported to CMS, 2019-2025
14 companies · $620 in 2025
The $620 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $666 · 2024: $732 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,825 · Consulting Fee: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,824.60 |
| Consulting Fee | $192.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $306.60 | 2023-2025 | Tezspire |
| Eisai INC. | $242.17 | 2024-2025 | |
| Novo Nordisk INC | $230.77 | 2023 | |
| Grifols USA, LLC | $217.26 | 2024-2025 | Gamunex-C, Xembify |
| Adma Biomanufacturing LLC | $192.76 | 2023-2025 | |
| Tg Therapeutics, INC. | $150.00 | 2025 | |
| Sanofi-Aventis U.S. LLC | $121.83 | 2024 | |
| Pharmacosmos Therapeutics INC. | $117.19 | 2023-2025 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $109.81 | 2025 | Hyqvia |
| Genzyme Corporation | $89.63 | 2024 | |
| Lundbeck LLC | $86.03 | 2023-2025 | Vyepti |
| Csl Behring | $66.47 | 2024-2025 | Hizentra, Haegarda |
| Genentech USA, INC. | $62.80 | 2023 | Xolair |
| Pharming Healthcare, INC. | $24.04 | 2025 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Van Fossen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.